Every 424B that Radiopharm Theranostics Limited (RADX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RADX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RADX filings page.
Radiopharm Theranostics Limited registered up to 1,345,728 ADSs for resale from time to time by the Selling Shareholders, representing 403,718,400 ordinary shares issuable upon exercise of Warrants. Each ADS represents 300 ordinary shares.
The Selling Shareholders receive all proceeds from ADS sales. Radiopharm may receive up to approximately US$5.1 million upon exercise of Warrants issued to the Selling Shareholders.
Radiopharm Theranostics Limited is conducting a primary offering of 1,281,646 American Depositary Shares (ADSs), representing 384,493,800 ordinary shares, at $3.16 per ADS, for gross proceeds of $4,050,001.36. Net proceeds are estimated at about US$3.3 million after placement agent fees and expenses.
In a concurrent private placement, investors receive unregistered Warrants to purchase up to 1,281,646 ADSs at an exercise price of $3.79 per ADS, expiring July 31, 2029, contingent on shareholder approval. Placement agent H.C. Wainwright earns a 7.0% cash fee plus expenses and Warrants to purchase 64,082 ADSs at $3.95 per ADS.
Proceeds are intended to fund preparation and readiness for the RAD101 registrational Phase 3 study, completion of RAD204 dose escalation, advancement of RAD202, RAD402 and RV01 programs, strategic partnering initiatives and general corporate purposes. An additional Australian private placement of A$6.7 million and a share purchase plan of up to A$6 million are also planned.
Radiopharm Theranostics Limited is amending its existing prospectus supplement to update the terms of an at-the-market equity program for its American Depositary Shares, or ADSs. Under this updated prospectus supplement, the company may sell ADSs having an aggregate offering price of up to $9,300,000 from time to time through or to Leerink Partners LLC, acting as sales agent or principal, under a December 16, 2025 sales agreement. Each ADS represents 300 ordinary shares. Leerink Partners will use commercially reasonable efforts to place the ADSs in transactions deemed an “at the market” offering and will receive a 3.0% commission on the gross sales price per ADS. As of July 7, 2026, the company’s public float was approximately US$40,165,592, and sales are subject to the one-third public float limitation under General Instruction I.B.5 of Form F-3. The ADSs trade on Nasdaq under the symbol RADX, where the last reported sale price on July 21, 2026 was $4.29 per ADS.